Comparison of PLGA and lecithin/chitosan nanoparticles for dermal targeting of betamethasone valerate

Journal of Drug Targeting

Volumn 21, Issue 6, 2013, Pages 542-550

  Özcan, Ipek ^a   Azizoǧlu, Erkan ^a   Şenyiǧit, Taner ^a   Özyazici, Mine ^a   Özer, Özgen ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Betamethasone valerate; in vivo evaluation; Lecithin chitosan nanoparticles; PLGA nanoparticles; Skin permeation

Indexed keywords

BETAMETHASONE VALERATE; CHITOSAN; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CREAM; DILUTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; EPIDERMIS; GEL; MALE; NONHUMAN; PARTICLE SIZE; PAW EDEMA; PRIORITY JOURNAL; RAT; SKIN PERMEABILITY;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE VALERATE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DERMIS; DRUG DELIVERY SYSTEMS; EPIDERMIS; LACTIC ACID; LECITHINS; MALE; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POLYGLYCOLIC ACID; RATS; RATS, WISTAR; SKIN ABSORPTION;

EID: 84879742251     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.769106     Document Type: Article

References (53)

1. Korting HC, Schaefer-Korting M. Carriers in the topical treatment of skin disease. Handb Exp Pharmacol 2010;197:435-68.
2. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev 2002;54:S41-55.
3. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-18.
4. Zhang W, Gao J, Zhu Q, et al. Penetration and distribution of PLGA nanoparticles in the human skin treated with microneedles. Int J Pharm 2010;402:205-12.
5. Hu Y, Hollinger JO, Marra KG. Controlled release from coated polymer microparticles embedded in tissue-engineered scaffolds. J Drug Target 2001;9:431-8.
6. Santos Maia C, Mehnert W, Schaller M, et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002;10:489-95.
7. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Del Rev 2004;56:675-711.
8. Puglia C, Blasi P, Rizza L, et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm 2008;357:295-304.
9. Choksi AN, Poonawalla T, Wilkerson MG. Nanoparticles: a closer look at their dermal effects. J Drugs Dermatol 2010; 9:475-81.
10. Neubert RHH. Potentials of new nanocarriers for dermal and transdermal drug delivery. Eur J Pharm Biopharm 2011;77:1-2.
11. Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids 2012;165:454-61.
12. Schneider M, Stracke F, Hansen S, Schaefer UF. Nanoparticles and their interactions with the dermal barrier. Dermato Endocrinol 2009;1:197-206.
13. Alvarez-Román R, Naik A, Kalia YN, et al. Skin penetration and distribution of polymeric nanoparticles. J Control Release 2004;99:53-62.
14. Schleich N, Preat V. Nanostructures overcoming the skin barrier: drug delivery strategies. In: Alonso MJ, Csaba NS, ed. Nanostructured biomaterials for overcoming biological barriers. Cambridge: Dorset Press; 2012:316-27.
15. Gupta H, Aqil M, Khar RK, et al. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target 2011;19:409-17.
16. Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012;161:505-22.
17. Luengo J, Weiss B, Schneider M, et al. Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin Pharmacol Physiol 2006;19:190-7.
18. Tomoda K, Terashima H, Suzuki K, et al. Enhanced transdermal delivery of indomethacin-loaded PLGA nanoparticles by iontophoresis. Colloids Surf B Biointerfaces 2011;88:706-10.
19. Hariharan S, Bhardwaj V, Bala I, et al. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res 2006;23:184-95.
20. Senyigit T, Sonvico F, Barbieri S, et al. Lecithin-chitosan nanoparticles of clobetasol-17-propionate capable of accumulation in pig skin. J Control Release 2010;142:368-73.
21. Hafner A, Lovric J, Pepic I, Filipovic-Grcic J. Lecithin/chitosan nanoparticles for transdermal delivery of melatonin. J Microencap 2011;28:807-15.
22. Schubert MA, Harms M, Müller-Goymann CC. Structural investigations on lipid NPs containing high amounts of lecithin. Eur J Pharm Sci 2006;27:226-36.
23. Tan Q, Liu W, Guo C, Zhai G. Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed 2011;6:1621-30.
24. Magdassi S, Bach U, Mumcuoglu KY. Formation of positively charged microcapsules based on chitosan-lecithin interactions. J Microencap 1997;14:189-95.
25. Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomed 2011;6:765-74.
26. Sezer AD, Cevher E. Topical drug delivery using chitosan nanoand microparticles. Exp Opin Drug Deliv 2012;9:1129-46.
27. Jensen LB, Petersson K, Nielsen HM. In vitro penetration properties of solid lipid nanoparticles in intact and barrier-impaired skin. Eur J Pharm Biopharm 2011;79:68-75.
28. Patel HK, Barot BS, Parejiya PB, et al. Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo: ex vivo permeation and skin irritation studies. Colloids Surf B Biointerfaces 2013;102:86-94.
29. Zhang J, Smith E. Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles. J Pharm Sci 2011;100:896-903.
30. Montenegro L, Ademola JI, Bonina FP, Maibach HI. Effect of application time of betamethasone-17-valerate 0.1% cream on skin blanching and stratum corneum drug concentration. Int J Pharm 1996;140:51-60.
31. Jain S, Mittal A, Jain AK. Enhanced topical delivery of cyclosporin-A using PLGA nanoparticles as carrier. Curr Nanosci 2011;7:524-30.
32. Sonvico F, Cagnani A, Rossi A, et al. Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction. Int J Pharm 2006;324:67-73.
33. Morris CJ. Carrageenan-induced paw edema in the rat and mouse from: methods in molecular biology. In: Winyard PG, Willoughby DA, ed. Inflammation protocols. Totowa: Humana Press Inc; 2003:115-21.
34. Schwarb FP, Smith EW, Haigh JM, Surber C. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data. Eur J Pharm Biopharm 1999;47:261-7.
35. Stolnik S, Garnett MC, Davies MC, et al. The colloidal properties of surfactant-free biodegradable nanospheres from poly(b-malic acid-co-benzyl malate)s and poly(lactic acid-co-glycolide). Colloids Surf A: Physicochem Eng Aspects 1995;97:235-45.
36. Park JS, Yang HN, Woo DW, et al. Multilineage differentiation of human derived dermal fibroblasts transfected with genes coated on PLGA nanoparticles plus growth factors. Biomaterials 2013;34:582-97.
37. Vandervoort J, Yoncheva K, Ludwig A. Influence of the homogenisation procedure on the physicochemical properties of PLGA nanoparticles. Chem Pharm Bull 2004;52:1273-9.
38. Menon JU, Kona S, Wadajkar AS, et al. Effects of surfactants on the properties of PLGA nanoparticles. J Biomed Mater Res A 2012;100A:1998-2005.
39. Wiedersberg S, Leopold CS, Guy RH. Dermatopharmacokinetics of betamethasone 17-valerate: influence of formulation viscosity and skin surface cleaning procedure. Eur J Pharm Biopharm 2009;71:362-6.
40. Hafner A, Lovrić J, Voinovich D, Filipović-Grcić J. Melatoninloaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers. Int J Pharm 2009;381:205-13.
41. Abdel-Mottaleb MMA, Neumann D, Lamprecht A. Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers. Eur J Pharm Biopharm 2011;79:36-42.
42. Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol 2010;27:247-59.
43. de Jalon EG, Blanco-Prieto MJ, Ygartua P, Santoyo S. Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers. J Control Release 2001; 75:191-7.
44. Jain S, Mittal A, Jain AK, et al. Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies. Curr Nanosci 2010;6:422-31.
45. Marimuthu M, Bennet D, Kim S. Self-assembled nanoparticles of PLGA-conjugated glucosamine as a sustained transdermal drug delivery vehicle. Polym J [Online] 2012. Available from: http://www.nature.com/pj/journal/vaop/ ncurrent/abs/pj2012103a.html/[last accessed 13 June 2012].
46. Tsujimoto H, Hara K, Haung CC, et al. Percutaneous absorption study of biodegradable PLGA nano-spheres via human skin biopsies. J Soc Powder Technol 2004;41:867-75.
47. Stracke F, Weiss B, Lehr CM, et al. Multiphoton microscopy for the investigation of dermal penetration of nanoparticle-borne drugs. J Invest Dermatol 2006;126:2224-33.
48. Sadeghi H, Hajhashemi V, Minaiyan M, et al. A study on the mechanisms involving the anti-inflammatory effect of amitriptyline in carrageenan-induced paw edema in rats. Eur J Pharmacol 2011;667:396-401.
49. Senyigit T, Tekmen I, Sonmez U, et al. Deoxycholate hydrogels of betamethasone-17-valerate intended for topical use: in vitro and in vivo evaluation. Int J Pharm 2011;403:123-9.
50. FDA guidance. Topical dermatologic corticosteroids: in vivo bioequivalence. 1995. [Online] Available from: http://www.fda. gov/cder/guidance/dd098fn.pdf [last accessed 2 June 1995].
51. Pershing LK, Bakhtian S, Poncelet CE, et al. Comparison of skin stripping, in vitro release and skin blanching response methods to measure dose response and similarity of triamcinolone acetonide cream strengths from two manufactured sources. J Pharm Sci 2002;91:1312-23.
52. Fresta M, Puglisi G. Corticosteroid dermal delivery with skin-lipid liposomes. J Control Release 1997;44:141-51.
53. Wickett RR, Nath V, Tanaka R, Hoath SB. Use of continuous electrical capacitance and transepidermal water loss measurements for assessing barrier function in neonatal rat skin. Skin Pharmacol 1995;8:179-85.